Open AccessPharmacology of anistreplase
Author(s) -
Sherry S.
Publication year - 1990
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.4960131303
Subject(s) - streptokinase , medicine , thrombolysis , thrombus , antithrombotic , fibrin , plasminogen activator , fibrinolytic agent , activator (genetics) , pharmacology , tissue plasminogen activator , immunology , myocardial infarction , receptor
Eminase (anistreplase), or anisoylated plasminogen streptokinase activator complex (APSAC), is a reversibly inactivated lys‐plasminogen‐streptokinase activator complex that is given rapidly over a period of 2–5 minutes, and has a half‐life in the circulation of 90–105 min. Eminase represents a significant advance in drug design for therapeutic thrombolysis based on convenience in administration, high gradient (especially initially) for diffusion into thrombus, improved fibrin binding, ability to lyse fibrin rapidly, improved stability in the circulation, long duration of action, and production of an antithrombotic state.